Connective Tissue Disease Market Key Manufactures Shares, Analysis And Forecasts Till 2023

 Connective tissues are a group of cellular congregations that provide support and structure to the human body. Connective tissue disease is a group of disorders which involves these protein rich tissues. Protein rich tissues play an important role of supporting organs and other parts of the body. Connective tissue disorders involves multiple organs and organ systems such as, skin, joints, muscles, lungs, kidneys, eyes, heart, gastrointestinal tract, and blood vessels. More than 200 disorders affect the connective tissues. According to a study published in Pan African Medical Journal in 2017, it is found that mixed connective tissue disorders are more frequent among Asians, and in the African population. It is also reported that among Asian population, the condition is more prevalent in China, and Japan. In the European region, the disorder is more prevalent in Italy, Hungary, Norway, and Poland.

Developments in the treatment of connective tissue diseases (CTDs) have been improved considerably, and the global connective tissue disease treatment market is slated to grow at a promising CAGR of 11.5% over the forecast period of 2017-2023. The cause of the disease is unknown and there's no cure for connective tissue disease yet, but medications are present to manage the signs and symptoms. CTDs include a large number of disorders which can affect different organs of the body. There is broad variability in disorders among patient suffering from CTDs.

It is estimated that connective tissue disease market is expected to grow at a CAGR 11.5% during the forecast period of 2017-2023.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/4977

A significant increase in the research and development efforts to find treatment and cure for CTDs have aided the growth of the market. Various therapy trials are underway which have been able to identify promising novel approaches to treat CTDs and are expected to boost the growth of the market. Rising prevalence of CTDs across the globe, especially in women has propelled the growth of the market. Additionally, support from governments across the world along with funds for R&D from the private industry is also a key driver of the growth of the market. With the increase in awareness and acceptance among the general population about connective tissue diseases, the diagnosed and drug-treated population will increase which will positively impact the market. Rising expenditure on healthcare, high unmet medical needs of the current treatment and growing prevalence of CTDs in Asia and Africa are expected to promote the growth of the market.  However, the growth of the market might be hindered by lack of a knowledgeable workforce, inadequate research and development infrastructure, lack of funds in middle and low-income countries.

Key Players

Some of key the players in the market are

• Abbott Laboratories
• Bayer AG
• Hoffmann-La Roche Ltd
• Pfizer
• AutoImmune Inc.
• Johnson & Johnson
• Amgen Inc.
• AstraZeneca
• Eli Lilly and Company
• Biogen
• LUPIN

Segmentation

The connective tissue disease market is segmented on the basis of diagnosis, treatment, and end-user.

On the basis of diagnosis, market is segmented into physical examination, X-ray examination, ANA (Antinuclear Antibody Test), and others.

On the basis of treatment, market is classified into non-steroidal anti-inflammatory drugs (NSAIDs), cortisone drugs/steroids, antimalarial drugs, cytotoxic drugs, and others

On the basis of end-user, market is segmented into hospital, diagnostic clinics, and others.

Regional Analysis

The Americas dominate the connective tissue disease market owing to the rising awareness among people, and increasing healthcare expenditure. As per the facts suggested by the Centers for Disease Control and Prevention (CDC), out of the total annual healthcare expenditure, 86% is for people with chronic health conditions in the United States.

Europe holds the second position in the connective tissue disease market. It is expected that the support provided by government bodies for research & development and improvement in reimbursement policies in healthcare will drive the market in Europe.

Asia Pacific is the fastest growing market connective tissue disease, owing to a huge patient pool, developing healthcare technology, and rising healthcare expenditure in some countries within this region. According to the Australian Institute of Health and Welfare, in the years 2015 to 2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than expenditure of 2014–15.

The Middle East & Africa has the lowest market for connective tissue disease due to lack of technical knowledge and poor medical facilities. 

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/connective-tissue-disease-market-4977 

Global Augmented Bone Graft Market Solid Segment Analyzed By Latest Trends, Growth Rate And 2023 Insight

 According to the British Editorial Society of Bone & Joint Surgery, bone is the second most common transplanted tissue after blood with an estimated 2.2 million grafting procedures worldwide annually as recorded in 2015. This development has been fuelled by the increasing cases of fractures and accidents around the world.

The Global Augmented Bone Graft Market is expected to grow at a CAGR of approximately 7.8% during the forecast period 2017-2023.

Augment Bone Graft is a combination drug/device product used for repairing the bone and reviving its regenerative properties. It is used as an alternative to autograft in arthrodesis of the ankle or hindfoot indicating the need for supplemental graft material. The use of augment bone graft eliminates the need for a second surgery to harvest autologous bone, thereby avoiding donor site morbidity. According to the National Health Interview Survey, in 2012, around 126 million adults were affected by this disease in the U.S. According to the Labor Force Survey (LFS), about 553,000 cases were registered for all work-related musculoskeletal disorder out of the total of 1,243,000 cases.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/4961

Allografts and bovine-derived bone graft products dominate the augmented bone graft market. These materials have variations in particle size which is their main drawback. The recent technological trend is to replace these natural materials with alloplastic bone grafts such as ceramics and polymers as they can be manufactured to the precise size and characteristics.

There has been increasing acceptance of bone grafting procedures which drives the market for augmented bone graft products. Many healthcare professionals have started using these bone grafts, especially in tertiary care centers and specialty hospitals which may promote and increase the demand for augmented bone graft. These bone graft works in a unique way to stimulate three key processes of early bone healing.

Various other factors such as, increasing advancement in technology, and rising adoption rate of new technology continuously contribute to the growth of this market. Despite these developments, high cost of surgeries and ethical issues related with bone grafting procedures may hamper the growth of the market. For instance, a study conducted by BMC Medical Ethics states that in a sample of 100 patients, about 20% of the patients refuse to accept allografts for their grafting surgery.

Additionally, stringent regulations obstruct the growth of augmented bone grafts market size and inadequate reimbursement policies for bone grafting also hampers the growth of global bone grafts market. Rapid product launches and increasing mergers and acquisitions between bone graft systems manufacturing companies are some of the major trends in the global bone grafts market.

The Key Players

• Zimmer Holdings, Inc.
• BioMimetic Therapeutics LLC
• Wright Medical Technology, Inc.
• Stryker Corporation, Smith & Nephew Plc
• RTI Surgical, Inc.,
• Olympus Biotech Corporation
• NuVasive, Inc.
• NovaBone Products LLC
• Medtronic, Inc.
• LifeNet Health, Inc.
• Integra LifeSciences Holdings Corporation
• Exactech, Inc.
• DePuy Spine, Inc.
• Synthes Inc.
• DePuy Synthes Companies
• Biomet, Inc.

Segmentation

The Augmented Bone Graft is segmented on the basis of products, application, and end-users.

On the basis of application, the market is segmented into the Craniomaxillofacial, Dental, Foot & Ankle, Joint Reconstruction, Long Bone, and Spinal Fusion

On the basis of product, the market is segmented into the Allografts, Bone Grafts Substitutes, and Cell-based Matrices. The Allografts segment is further sub divided into Machined Allografts and Demineralized Bone Matrix. The Bone Grafts Substitutes is also sub categorized as Bone Morphogenic Proteins (BMP) and Synthetic Bone Grafts.

On the basis of end-user, the market is segmented into hospitals, clinics, ambulatory surgical centers and others.

Regional Analysis

The Global Augmented Bone Graft Market consists of countries namely America, Europe, Asia Pacific, and the Middle East.

North America dominated the global augmented bone graft market owing to the increasing healthcare expenditure in North America since 2016. Canadian healthcare specifically was stressed by an advancing demographic move. The increase of insurance coverage because of health care reform (Affordable Care Act) in the United States additionally prompted an expansion in health care spending. In 2016, healthcare organizations found liberation from a special tax on medical devices (Medical Device Excise Tax). The United States Congress put off the tax for a long two years in 2015.

For Europe, the healthcare spending has expanded slightly in Germany. Neverthelss, the orthopedic biologics market including the bone graft substitute market has been determined by solid strong competition and price pressure. While volume of sales and the scope of new treatment techniques are on the ascent, net revenues in the German market are declining. Western Europe continues to see a need to save money on healthcare because of a slight drop in financial growth and obstinate economic pressure.

Healthcare spending in Asia expanded in 2016 due to an extension of state health care programs and the increasing affluence of the population. India, in specific, saw an expansion in spending due to a government resolution to enhance healthcare services.

Furthermore in the Middle East & Africa the spending for healthcare was also increased. This was essentially because of elections in a few nations, (for example, Ghana, Niger, Uganda, Zambia and Somalia), healthcare growth and population growth. Awareness for medicinal technology likewise expanded extraordinarily. Due to of low local production, the region is dependent on imported medicinal products. The import standard in numerous nations is 80% to 90%.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/augmented-bone-graft-market-4961

Worldwide Acute Care Electronic Market Segmentation And Analysis By Recent Trends And Growth Prospects By Regions To 2023

 Acute care EHR is different from its traditional counterparts. The acute care EHR allows healthcare professionals to collect, preserve and access vital patient clinical data in acute care and ambulatory care settings. Market Research Future (MRFR) perceives the global acute care EHR market to register a CAGR of 7% over the forecast period of 2017-2023.

The global acute care EHR market share  driven by the surging incidences of chronic diseases on a global scale. In recent years, the prevalence of chronic diseases such as cancer, diabetes, and cardiovascular disease have been on the rise which has consequently raised the number of healthcare institutions. Growth in a number of hospitals and other medical centers have created massive demand for management of patient data which boosts the growth of the global acute care EHR market. The rise in global geriatric population is also a contributing factor to the growth of the global acute care EHR market. The aged population who are more susceptible to suffer from chronic diseases have induced high demand for remote monitoring of geriatric patient data. Factors such as development in healthcare IT, technological advancements and expanding expenditure on healthcare act as a plus for the growth of the market. On the contrary, the growth of the global acute care EHR market might be restrained by high costs associated with acute care EHR solutions which might limit the growth of the market in price-sensitive market. Furthermore, towering costs of healthcare devices and treatments are also likely to hinder market growth.

 

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/4930

 

Competitive Landscape

The noteworthy players in the global acute care EHR market include Epic Systems Corporation (U.S.), Evident (CPSI) (U.S.), eClinicalWorks (U.S.), Medhost (U.S.), Athenahealth (RazorInsights) (U.S.), IBM (U.S.), Vitera Healthcare Solutions (U.S.), Meditech (U.S.), McKesson Corporation (U.S.), Allscript (U.S.), Cerner Corporation (Siemens) (U.S.), Healthland (U.S.), and General Electric Company (U.S.).

 

Segmentation

The global acute care EHR market has been segmented based on deployment, application, and end user.

 

By deployment, the global acute care EHR market has been segmented into On-Premises based and Web-based.

 

By application, the global acute care EHR market has been segmented into personal care, pharmaceuticals, and others.

 

By end user, the global acute care EHR market has been segmented into hospital, ambulatory care, and others.

 

Regional Analysis

The Americas dominate the global acute care EHR market owing to the increasing number of hospitals ambulatory centers, presence of huge patient population and well developed technology. The hospital and clinics are able to afford the cost of the devices as these are funded by several sources: the public sector, charities, health insurance companies, health organizations of all kinds, etc. Additionally, the people in this region are able to afford high cost of treatment on account of higher per capita income in this region. Rapidly increasing patient population, governments have started supporting the manufacturers for the development of new and better devices which has driven the growth of the market. Moreover, well developed technology, high healthcare expenditure, and huge geriatric population have fuelled the growth of the market in this region.

Asia Pacific is the fastest growing acute care EHR market owing to the increasing number of patients suffering from chronic diseases and rapidly increasing number of hospitals & clinics. Additionally, rapidly growing economies and increasing healthcare expenditure will fuel the growth of the market. On the other hand, the Middle East & Africa hold the least share of the market owing to less availability of funds, limited availability of medical facilities, and poor political conditions in Africa.

Europe commands the second largest market for acute care EHR which is followed by Asia Pacific. Availability of funds, strong government support, and increasing need for the better management devices & platform drive the growth of the market in Europe. Western Europe holds a major share of the market due to the presence of well developed economies. U.K, Germany and France are the major contributors of the market.

Industry Updates

• In November 2018, ResMed, a company that specializes in connected devices and remote monitoring for sleep apnea and respiratory illnesses announced the acquisition of MatrixCare’s post-acute care EHR solution for USD 750 million.

 

• In December 2018, Allscripts, a provider of healthcare solutions, announced selling of its stake in post-acute care EHR vendor Netsmart to TA Associates and GI Partners, both private equity firms for a total amount of USD 525 million.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/acute-care-ehr-market-4930 

Retropharyngeal abscess Industry Growth, Trends And Forecast Till 2023 By Marketresearchfuture.Com

 Market scenario:

Retropharyngeal abscess is a serious infection deep in the neck and generally occurs in children under age eight, though it can also affect adults. The symptoms include difficulty in breathing and swallowing, pain, severe cough and throat pain, neck stiffness and spasms and others. If left untreated, retropharyngeal abscess infection can result in septic shock, organ failure and death. Retropharyngeal abscess recurs in an estimated 1 to 5% of patients and such patients are 40 to 50% more likely to die due to abscess-related complications.

The Latest report by Market Research Future (MRFR) asserts that, The global retropharyngeal abscess market is expected to reach USD 5.9 billion by 2023, and the market is projected to grow at a CAGR of ~ 4.5 % during the forecast period 2017-2023.

The market drivers include rise in demand due to growing young and immune-compromised population, increasing screening, and others. The market restraints are the complications such as risk of bleeding, pain, especially during surgery, high cost of treatment, poor healthcare penetration and others.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/4922

Development of antibiotics resistant bacteria is the single most unmet need of the market. Product development represents the best strategy for the market growth. The market is expected to witness exponential growth over the review period owing to development of selective gram negative antibiotics. Market development is another strategy for as there is a large unmet need in the developing regions such as India and China. Cost of the product will be a decisive factor in the developing regions such as Asia Pacific and especially Africa.

Key Players

• Merck KGaA,
• Johnson & Johnson,
• AstraZeneca plc,
• Sanofi S.A.,
• Pfizer,
• Mylan N.V,
• Novartis AG,
• Teva pharmaceutical company,
• GlaxoSmithKline plc.

Segments

The global retropharyngeal abscess market has been segmented on the basis of diagnosis, treatment, and end user.

Based on the diagnosis, the market has been segmented as X-rays and computed tomography, blood tests, physical exam and others.

Based on the treatment, the market has been segmented as calcium antibiotics, pain killers, surgical drainage and others.

Based on the end user, the market has been segmented as hospitals and clinics, research and academics and others.

Regional Analysis

Asia Pacific retropharyngeal abscess market size is expected to grow rapidly; China and India are likely to lead this market due to fast growing healthcare sector and large unmet needs over the forecast period. South East Asian countries such as China, India, and Malaysia are projected to contribute highly to the market growth. The growing penetration of healthcare industry in the Asia Pacific region is expected to drive the future retropharyngeal abscess market in the region. However the low expenditure on healthcare coupled with the poor incomes in the developing regions is a dent on the market.

A significant market share of the global retropharyngeal abscess market is held by the Americas, owing to high expenditure on the health care especially in major countries of the region like the U.S. and Canada. Additionally, the number of cardiac procedures in the U.S and Canada is increasing due to greater healthcare penetration, which drives the retropharyngeal abscess market. The high concentration of the major hospitals in the developed countries of this region coupled with good reimbursement rates is adding fuel to the market growth. Moreover, the large share of infective procedures treatment in the returns of hospitals favors the market. The large number of pharmaceutical companies in the U.S. is also a cause for the faster development of retropharyngeal abscess market in the US. The development of broad spectrum antibiotics in developed regions such as the U.S. and Europe is a strong driver of the market.

Europe is the second largest market in the world due to growing pharmaceutical industry and healthcare penetration. The European market growth is led by countries such as Germany and France. Germany is expected to be the fastest growing market over the assessment period due to its large pharmaceutical and microsurgery devices industry. The development of Methicillin-resistant Staphylococcus aureus (MRSA) especially in the southern regions of Europe such as Spain, Italy etc. stimulates the market.

Gulf nations such as Saudi Arabia and the UAE are estimated to drive the Middle East & African market. Other Middle East nations to watch out for are Kuwait, Jordan, Egypt and Iran. The African region is expected to witness a poor growth owing to poor economic and political conditions, and poor healthcare development. Other regions are expected to be laggards due to poor social development and tribal identities such as sub Saharan Africa.

Access More Details of the Report @ https://www.marketresearchfuture.com/reports/retropharyngeal-abscess-market-4922

Encephalomyelitis Market 2019 – Leading Manufactures, Regions, Drivers, Analysis And Forecasts Till 2023

 Market Scenario

Encephalomyelitis is brain or spinal cord inflammation caused due to virus, infections, and other foreign particles. The patient suffering from autoimmune diseases and AIDS are more prone to the diseases. A wide range of drugs are available for the treatment of this disease, however no precise treatment is available to cure the disease. Increasing prevalence of encephalomyelitis and autoimmune diseases has boosted the growth of the market. According to the WHO, 4.3 million people across the globe are affected by this disease. Additionally, changing lifestyle, increasing geriatric population, increasing need for better treatment has driven the global market. Moreover, increasing government support along with the per capita income have fuelled the market growth. However, limited and high cost of treatment options may retard the growth of the market over the assessment period.

The global encephalomyelitis market is expected to grow at a CAGR of ~8.1 % during the forecast period 2017-2023. 

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/4874

Segmentations

The global encephalomyelitis market is segmented on the basis of types, treatment and end users.

On the basis of treatment, the market is segmented into drug treatment, plasmapheresis, surgery, and others. Drug therapy is further segmented into antiviral medications, antibiotics, steroids, sedatives, NSAIDs, mood stabilizers, and others.

On the basis of types, the market is segmented into acute disseminated encephalomyelitis, encephalomyelitis disseminata, antiMOG associated encephalomyelitis, equine encephalomyelitis, AIDS related encephalomyelitis and others.

On the basis of end users, the market is segmented into hospital, clinics and others.

Regional Analysis

The Americas command a major of the Encephalomyelitis market share owing to the large patient population, growing prevalence of encephalomyelitis & autoimmune diseases, and strong government support for research & development. According to the American Autoimmune Related Diseases Association, approximately 50 million people in the U.S. were reported to be suffering from autoimmune diseases in 2014.

Europe accounts for the second largest market across the globe, which is followed by Asia Pacific. Strong government support, availability of funds for research and high healthcare expenditure drives the growth of the market. Asia Pacific is the fastest growing market. China, and India are the key contributors to the market growth due to presence of huge population base, increasing prevalence of AIDS and autoimmune diseases, rapidly growing economy, and increasing healthcare expenditure. Additionally, increasing government support, and presence of huge opportunity have fuelled the growth of the market in Asia Pacific.

The Middle East & Africa holds the least share of the global market due to limited availability of medical facilities and poor economic condition in African region. The UAE, Saudi Arabia, and Kuwait are expected to drive the Middle East & African market owing to the well-developed economy and high healthcare spending.

Key Players

Some of key the players in the market are Bristol-Myers Squibb Company (U.S.), Sanofi (France), GlaxoSmithKline Plc. (U.K), Spectrum Pharmaceuticals Inc. (U.S.), Amgen, Inc. (U.S.), Merck & Co., Inc. (U.S.), Bayer AG (Germany), Novartis AG (Switzerland), F. Hoffmann-La Roche Ltd. (Switzerland), Eli Lilly and Company (U.S.), AstraZeneca Plc. (U.K), Janssen Biotech, Inc. (U.S.), AbbVie Inc. (U.S.), Takeda Pharmaceuticals (Japan), Immunomedics (U.S.), Pfizer, Inc. (U.S.), and Oncomed Pharmaceuticals (U.S.).

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/encephalomyelitis-market-4874

Medical Tricorder Market Shares Analysis, Key Development Strategies And Forecasts Till 2023

 Market Synopsis of Global Medical Tricorder Market

Medical device used by the consumer to self-diagnose medical condition is known as a medical tricorder. It takes basic vital measurement like heart rate and body temperature within seconds. Major functions of a medical tricorder are to monitor health of a person, summarize patient’s health, diagnose disease and take health measurements. Furthermore, rapid development in technology, increasing government support for research & development, changing lifestyle, and many adverse effects of the present diagnostic methods expected to fuel the market growth during the forecast period.

Medical Device Industry is flourishing across the globe owing to an increasing demand for technologically advanced devices, extensive use of smart medical devices, and overall improvement in healthcare sector. Various smart devices are used to determine the heart rate, glucose levels in the body, and other parameters.

Global medical tricorder industry is expected to reach USD 5.4 billion in 2023 from USD 2.5 billion in 2016 with a CAGR of approximately 6.7% during the forecast period 2017-2023.

However, these types of devices has to pass all the regulatory standards and rules, which increases the approval time. The average approval time for the medical diagnostic device may vary from 5-8 years. This long approval time, high cost of the research & development and devices may hamper the market growth during the corresponding period.

The demand of medical tricorder is increasing because of an increase in the demand medical tricorder among health care providers, helping them to diagnose patient’s health condition, increasing outpatient services in the hospitals, increase in patient pool suffering from diabetes, and cardiovascular diseases, and demand for new technology for diagnoses and monitoring.

According to findings from the WHO, in 2014, approximately 422 million people suffered from diabetes across the globe.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/1220  

Global Medical Tricorder Market – Regional:

Geographically, the regional market is segmented into America, Europe, Asia Pacific, and the Middle East & Africa.

America is the largest market which is attributed to extensive use of medical tricorder by number of physicians in America. Increasing in patient pool, increase in outpatient services and concentration of major market players of medical tricorder in North America drive this market in America. North America is the largest market whose growth is attributed to an increase in patient pool, and demand for improved technology for diagnosis of ongoing health of a patient drive this market in America. According to the American Diabetes Association, in 2015, approximately 30.3 million Americans which is 9.4% of the American population were suffering from diabetes 

The European market is also growing continuously and slowly catching up with the American market in the near future. Emphasis for early diagnosis of disease condition and awareness regarding the use of tricorder. Extensive research in innovative product development, and adoption of new technologies in healthcare institutes such as hospitals & clinics, research institutes, clinical laboratories, diagnostics center and home care settings. QuantuMDx Group Ltd. is in Europe. It is one of the major market players for medical tricorder, thus favoring the opportunities for research and development activities in the field of medical devices and molecular diagnosis.

Asia-Pacific market is expected to show steady growth in the medical tricorder market during the forecasted period owing to the rising prevalence of chronic diseases such as obesity, diabetes, cardiovascular diseases, growing geriatric population, and development in healthcare sector. China and India are expected to be the emerging market in Asia Pacific, owing to the increasing number of patients diagnosed with chronic diseases, and high growth potentials supported by favourable macro-economic conditions.

Middle East & Africa show slow growth in this market owing to demand for primary care services for the diagnosis and treatment of chronic diseases, and rising awareness about preventive measures for various diseases, and increasing emphasis on women and child care.

Global Medical Tricorder Market: Company Analysis

Ibis Biosciences, Inc. provides molecular diagnostics, offers instruments and reagents to analyze DNA and RNA for clinical specialists and laboratory. In February 2016, the company won a USD 2,124,718 federal contract from the Defense Advanced Research Projects Agency, Arlington, Virginia for R&D.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/medical-tricorder-market-1220

Worldwide Bone Density Test Market 2019 Synopsis With Leading Players, Industry Growth Factor Foresight By 2023

 Recognizing the exponential growth, the market perceives currently and gauging the potential the market holds to grow in the years to come. Recent technological advancements and bone density test market trends have boosted the Bone Density Test market size, increasing the uptake of bone density test.  Besides, increasing prevalence of osteoporosis, osteopenia, hyperthyroidism, and increasing demand for portable bone testing devices foster the market growth.  Moreover, the demand for diagnosis and treatment measures for osteoporosis escalates the market growth of the bone density test on the global platform.

Market Research Future (MRFR), in its recently published market forecast asserts that the global bone density test market will grow exponentially by 2023, registering approximately 7.2% CAGR during the review period (2017 – 2023).

Additional factors substantiating the market growth include the demand for technologically advanced devices and growing geriatric populace.  Also, substantial technological strides being made in electronic monitoring devices and substantial investments transpired into R&D activities are in turn, paying off well, expanding the market size.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/4766

Bone density test provides more of a high-level overview and in-depth details on more specific aspects of bone health alongside indicating current and potential health risks such as Low bone mineral density, Osteoporosis, and Hyperthyroidism.  A stress fracture or other bone issue is often the initial reason that can cause impaired bone health and can affect bone density in the future. All these factors indicate that a bone is not as strong as normal bone and places that are at risk for stress fractures or other broken bones.

Furthermore, the ever-increasing population that is increasingly adopting the sedentary lifestyle and urbanization are supporting the market growth. Improving economic conditions are providing impetus to the market growth, increasing the healthcare expenditures and availing rapid access to the excellent health care.

On the other hand, limited or no awareness of the advantages of bone density test is impeding the market growth.  Also, the unmet clinical needs coupled with the unavailability of external funding are acting as a headwind to the market growth, especially in the developing regions. Nevertheless, increasing demand for portable and hand-held diagnostic devices alongside the augmenting demand for the bone density test in the diagnostics to obtain fastest & accurate results is expected to fuel the market growth. 

Competitive Analysis

The market for bone density test appears fragmented and fiercely competitive due to many large and small players churning the competition in the market.  Through the strategic partnership, acquisition, expansion, product & technology launch, and collaboration, these players try to gain the competitive edge.

The global bone density test market is led by some of the fervent players like

• Hologic Inc. (U.S),
• General Electric Company (U.S.),
• BeamMed Ltd.  (Israel),
• Osteosys Corp (South Korea),
• Swissray (U.S.),
• DMS Imaging (France),
• Osteometer Meditech Inc. (U.S),
• Medonica Co. LLTb (South Korea),
• Lone Oak Medical Technologies, LLC (U.S.).

 

Global Bone Density Test Market – Segments

The market can be segmented into five key dynamics for the convenience of understanding;

By Types                   : Central Dual-Energy X-Ray Absorptiometry (DXA), Peripheral Tests {peripheral dual-energy X-ray absorptiometry (pDXA), quantitative ultrasound (QUS), peripheral quantitative computed tomography (pQCT), others} and Radiographic Absorptiometry among others.

By Indications    : Osteoporosis, and Hyperthyroidism, others.

By Devices               : Central DEXA Scan Machine and others.

By End-Users          :  Hospitals, clinics, and diagnostic centers, among others.

By Regions              :  North America, Europe, APAC and the Rest-of-the-World (RoW).

Regional Analysis

The North American region is estimated to retain its dominance over the global bone density test market with the largest market share. A well-developed healthcare sector, increasing prevalence of diseases and disorders related to bones such as osteoporosis, osteopenia, and hyperthyroidism along with the high per capita healthcare expenditures drive the market growth in the region. The region is expected to create a substantial revenue pocket registering a strong CAGR throughout the forecast period (2017-2023). Furthermore, the presence of prominent market players especially in the U.S. & Canada impacts the market growth positively. 

The European region accounts for the second-largest market for bone density test, emerging as another lucrative market, globally. The U.K., backed by its sizeable vast bone density test market and Germany with its vast medical device industry is expected to drive the market growth in the region. Favorable governmental support and initiatives drive the growth in the market extensively. The proliferating healthcare sector in the region, backed by the resurging economy is fostering the market growth radiantly.

The Asia Pacific region is emerging as a promising market for bone density test owing to the rising prevalence of osteoporosis in women after menopause. Furthermore, increasing awareness towards women healthcare and nutrition influences the market growth. Changing lifestyle and overall development of medical device industry supports the growth of the market in the region.  Besides, the increasing healthcare expenditures and favorable government policies of developing economies like India and China substantiate the market growth in the APAC region.

Browse more details of Bone Density Test Market @ https://www.marketresearchfuture.com/reports/bone-density-test-market-4766